Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer

Heidi H. Van Ojik, Roland Repp*, Gerard Groenewegen, Thomas Valerius, Jan G.J. Van De Winkel

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)
Original languageEnglish
Pages (from-to)207-209
Number of pages3
JournalCancer Immunology Immunotherapy
Volume45
Issue number3-4
DOIs
Publication statusPublished - 18 Dec 1997

Keywords

  • Bispecific antibody
  • FcγRI
  • Immunotherapy
  • Neutrophil
  • Phase I trial

Cite this